...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Phase I Study of S-1 plus Fractional Cisplatin as Adjuvant Chemotherapy for Advanced Gastric Cancer in an Outpatient Setting (KOGC-03)
【24h】

Phase I Study of S-1 plus Fractional Cisplatin as Adjuvant Chemotherapy for Advanced Gastric Cancer in an Outpatient Setting (KOGC-03)

机译：S-1加分数顺铂作为门诊晚期胃癌辅助化疗的I期研究（KOGC-03）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The aim of this phase I study was to adjust the dose of cisplatin as adjuvant combination chemotherapy with S-1 in an outpatient setting for gastric cancer. Patients and Methods: The first course was initiated with S-1 monotherapy on days 1-28. From the second to the sixth course, S-1 was administered on days 1-28 and cisplatin was added on days 1, 15, and 29. The dose level of cisplatin was escalated as follows: 20 mg/m(2) (level I); 25 mg/m(2) (level 2); 30 mg/m(2) (level.3). Dose-limiting toxicity was a delay factor of the start of the next course due to incomplete recovery. Results: The maximum tolerated and recommended doses were confirmed as level 3 and level 2, respectively. Conclusion: Although further clinical trials are recommended to evaluate efficacy, this combination of S-1 plus cisplatin regimen is expected to become a standard adjuvant treatment for gastric cancer in the outpatient setting.
机译：目的：该I期研究的目的是在门诊胃癌患者中调整顺铂作为S-1辅助联合化疗的剂量。患者和方法：第一个疗程在1-28天以S-1单一疗法开始。从第二个疗程到第六个疗程，在第1-28天服用S-1，并在第15天，第15天和第29天添加顺铂。顺铂的剂量水平逐步提高如下：20 mg / m（2）（水平一世）; 25 mg / m（2）（2级）; 30 mg / m（2）（第3级）。由于恢复不完全，限制剂量的毒性是下一疗程开始的延迟因素。结果：最大耐受​​剂量和推荐剂量分别确定为3级和2级。结论：尽管建议进行进一步的临床试验以评估疗效，但这种S-1加顺铂方案的组合有望在门诊患者中成为胃癌的标准辅助治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号